The importance of microtubules in cell division, motility, intracellular trafficking, and their role in modulating cellular shape according to the environment has made them one of the most successful targets of anticancer therapy. Agents that perturb the microtubule dynamics have been widely used in cancer treatment. Considering the relative success of mitotic agents in the treatment of cancer, microtubules may
be termed as one of the best cancer targets identified till now.
Microtubule targeting agents can be broadly classified into two major classes. The first class consists of microtubule-destabilizing agents, which inhibit microtubule polymerization. This class of anti-mitotic drugs includes several compounds such as the vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine, vinflunine), estramustine, colchicine and combretastatins, that are being used clinically or
are under clinical investigation for cancer treatment. The second class is comprised of microtubule-stabilizing agents. These agents include paclitaxel, docetaxel, epothilones, and discodermolide. The consequence of disrupting tubulin and microtubule dynamics with both these classes of drugs in dividing cells is metaphase (cell division) arrest and induction of apoptosis (cell self-destruction).
Fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)
carbamate) is a broad-spectrum benzimidazole anthelminthic (anti-parasitic) approved for use in numerous animal species. Repurposing of veterinary drugs showing promising results for human use can result in considerable time and cost reduction required to develop new drugs. Fenbendazole is known to have a high safety margin and most species tolerate it very well. It has very low degree of toxicity and high degree of safety in experimental animals. In this study, we show that fenbendazole (FZ)
exhibits a moderate micro-tubule de-polymerizing activity towards human cancer cells but possesses a potent anti-tumor effect as evident from in vitro and in vivo experiments. Our results indicate that FZ exerts its antitumor effect through the disruption of microtubule dynamics, p53 activation and the modulation of genes involved in multiple cellular pathways. FZ treatment also resulted in reduced glucose uptake in cancer cells due to down regulation
of GLUT transporters and key glycolytic enzymes.
My prostate cancer continued to persist over the years. I’ve used PNC-27, Foxo4-DIR, Two Feathers and Ozone Rectally to cause the cancer and enlargement of my prostate to regress. However, once I started to use Fenbendazole at a rate of 444mg 2x per day, is when I started to notice a regression of my prostate size and a return of more ease of urine flow.
Therefore, I now recommend for the eradication of all cancers in the body to take Fenbendazole Power at the rate of use either 222mg or 444 mg 2-3x per day with. Because Fenbendazole has an irritating effect on the digestive tract, dosage can vary according to what you tolerate from 222mg to 444 mg 2-3x per day. I recommend taking this at the end of your meals. This causes it to mix with the food in your stomach and is therefore less irritating
to your intestines.
https://www.nature.com/articles/s41598-018-30158-6